

DETAILED ACTION

Status of the Claims

1. Claims 1-3, 6-8, 10-23 and 27-34 are pending.

Applicants' amendment filed August 12, 2011 is acknowledged. Applicant's response has been fully considered. Claims 1, 6, 17, 21-23, 27 and 31-34 have been amended. Therefore, claims 1-3, 6-8, 10-23 and 27-34 are examined.

Withdrawn Claim Objections

2. The previous objection to claims 12, 13, 15, 21-23, 27, 33 and 34 is withdrawn in view of applicants' amendment to the claim, and applicants' response at page 6 in the amendment filed August 12, 2011.

Withdrawn Claim Rejections - 35 USC § 112

3. The previous rejection of claims 1-3, 6-8, 10, 11, 14, 15, 18-23 and 27-34 under 35 U.S.C. 112, first paragraph, scope of enablement, is withdrawn in view of applicants' amendment to the claims, and applicants' response at pages 6-7 in the amendment filed August 12, 2011.
4. The previous rejection of claims 2, 3, 7, 8, 22 and 32 under 35 U.S.C. 112, second paragraph, is withdrawn in view of applicants' amendment to the claim, and applicants' response at page 7 in the amendment filed August 12, 2011.

The following is an Examiner's Statement of Reasons for Allowance: The following reference is the closest art to the claimed invention. Ruppert *et al.* (Thrombosis and Hemostasis 89, 53-64 (2003)) teach a hybrid molecule is obtained by chemical cross-linking of a mammalian pulmonary surfactant protein such as the mature surfactant protein SP-B and a mammalian plasminogen activator such as B chain of urokinase plasminogen activator. However, Ruppert *et al.* do not disclose a fusion protein comprising a surfactant protein precursor N-terminally fused

Art Unit: 1656

to a plasminogen activator or comprising a mature surfactant protein N-terminally or C-terminally fused to a plasminogen activator. Therefore, the claims are allowable over the art of record.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chih-Min Kam whose telephone number is (571) 272-0948. The examiner can normally be reached on 8.00-4:30, Mon-Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Manjunath Rao can be reached at 571-272-0939. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Chih-Min Kam/

Primary Examiner, Art Unit 1656

CMK

October 6, 2011